Sugi Predict

Sugi Predict / Compounds / SCHEMBL1076153

SCHEMBL1076153

SCHEMBL1076153

Cc1noc(C)c1-c1c(C(N)=NO)c2cccc(F)c2n1-c1ccc(O)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 1/20 0.35
▸ BRD4 O60885 3/20 0.34
▸ CYP1A2 P05177 4/20 0.33
▸ CYP2C19 P33261 3/20 0.33
▸ USP2 O75604 3/20 0.33
▸ ALOX15 P16050 3/20 0.33
▸ HSD17B10 Q99714 3/20 0.33
▸ LMNA P02545 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ APEX1 P27695 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ESR1 P03372 2/20 0.32
▸ FTO Q9C0B1 1/20 0.32
▸ CYP3A4 P08684 3/20 0.31
▸ CLK4 Q9HAZ1 3/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1076148 1.00 PIK3CD (0.35) PIK3CDBRD4CYP1A2CYP2C19USP2
SCHEMBL2307797 0.86 ERN1 (0.34) PIK3CDBRD4
SCHEMBL2312965 0.86 ERN1 (0.34) PIK3CDBRD4
SCHEMBL2313824 0.85 BRD4 (0.34) PIK3CDBRD4ESR1FTOBRD2
SCHEMBL2311182 0.85 BRD4 (0.34) PIK3CDBRD4ESR1FTOBRD2
SCHEMBL1077420 0.84 ESR1 (0.38) BRD4CYP1A2CYP2C19USP2ALOX15
SCHEMBL1077417 0.84 ESR1 (0.38) BRD4CYP1A2CYP2C19USP2ALOX15
SCHEMBL13667933 0.84 PIK3CD (0.38) PIK3CDBRD4CYP1A2CYP2C19USP2
SCHEMBL1667699 0.83 BRD4 (0.36) BRD4CYP1A2CYP2C19USP2ALOX15
SCHEMBL1667700 0.83 BRD4 (0.36) BRD4CYP1A2CYP2C19USP2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP claimed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US claimed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US claimed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US claimed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US claimed
EP-3782616-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2023-11-01 — — EP disclosed
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-04-18 — — US disclosed
EP-3782616-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES The Regents of The University of California (US) 2021-02-24 — — EP disclosed
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-01-14 — — US disclosed
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-09-01 — — US disclosed
EP-3189026-B1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES UNIV CALIFORNIA (US) 2020-07-22 — — EP disclosed
US-20170304216-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-10-26 — — US disclosed
WO-2016036721-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-03-10 — — WO disclosed
EP-2276732-B1 NOVEL ESTROGEN RECEPTOR LIGANDS KAROBIO AB (SE) 2015-05-20 — — EP disclosed
US-8653072-B2 Estrogen receptor ligands KARO BIO AB (SE) 2014-02-18 — — US disclosed
US-20130131061-A1 Novel Estrogen Receptor Ligands KARO BIO AB (SE) 2013-05-23 — — US disclosed
US-8367665-B2 Estrogen receptor ligands KARO BIO AB (SE) 2013-02-05 — — US disclosed
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS OASMIA PHARMACEUTICAL AB (SE) 2011-08-04 — — US disclosed
EP-2276732-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2011-01-26 — — EP disclosed
WO-2009127686-A1 NOVEL ESTROGEN RECEPTOR LIGANDS KARO BIO AB (SE) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210008002-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 PIK3CD 4424/4885BRD4 1609/4885CYP1A2 2051/4885
US-20170304216-A1 ESTROGEN RECEPTOR LIGAND TREATMENT FOR NEURODEGENERATIVE DISEASES ESR2, ESRRG, ESR1 PIK3CD 4424/4885BRD4 1609/4885CYP1A2 2051/4885
US-11628146-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 PIK3CD 4424/4885BRD4 1609/4885CYP1A2 2051/4885
US-20130131061-A1 Novel Estrogen Receptor Ligands ESR1, GPER1, ESRRA PIK3CD 3789/4885BRD4 713/4885CYP1A2 1101/4885
US-20110190294-A1 NOVEL ESTROGEN RECEPTOR LIGANDS ESR1, GPER1, ESRRA PIK3CD 3760/4885BRD4 628/4885CYP1A2 1096/4885
US-10758496-B2 Estrogen receptor ligand treatment for neurodegenerative diseases ESR2, ESRRG, ESR1 PIK3CD 4424/4885BRD4 1609/4885CYP1A2 2051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.